Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study.
Acquired Immunodeficiency Syndrome
/ blood
Adolescent
Adult
Anti-HIV Agents
/ adverse effects
China
/ epidemiology
Drug Resistance, Viral
/ genetics
Female
Genes, pol
Genetic Variation
HIV-1
/ genetics
Humans
Infectious Disease Transmission, Vertical
/ prevention & control
Male
Minority Groups
Mutation
Prevalence
Reverse Transcriptase Inhibitors
/ adverse effects
Treatment Outcome
Young Adult
Antiretroviral therapy
Drug resistance
HIV
HIV-1 subtypes
Virological failure
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
23 Jun 2020
23 Jun 2020
Historique:
received:
27
01
2020
accepted:
27
05
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
7
7
2020
Statut:
epublish
Résumé
Liangshan Yi Autonomous Prefecture is one of the areas that most severely affected by human immunodeficiency virus (HIV) in China, and virological failure on antiretroviral therapy (ART) is serious in this area. Analyses of prevalence and determinants of ART failure, the genetic diversity and drug resistance among people living with HIV (PLWH) helps improve HIV treatment efficiency and prevent HIV transmission. A total of 5157 PLWH were recruited from 2016 to 2017. The venous blood samples were subjected to RT-PCR, followed by sequencing of the HIV-1 pol gene, targeting the protease and reverse transcriptase fragments. HIV-1 diversity was analyzed using the DNAStar software and drug resistance mutations were analyzed using the Stanford University HIV Drug Resistance Database. A total of 2156 (41.81%) PLWH showed virological failure on ART. Males (ORm = 1.25), heterosexual behaviors and drug injection (ORm = 1.44) and mother to child transmission routes (ORm = 1.58), the clinical stage of AIDS (ORm = 1.35), having used illicit drugs and shared the needles (1-4 times: ORm = 1.34; more than 5 times: ORm = 1.52), having ever replaced ART regimen (ORm = 1.48) increased the risk of virological failure among PLWH, while higher education lever (ORm = 0.77) and ≥ 12 months on ART (12 ~ 36 months: ORm = 0.72; ≥36 months: ORm = 0.66) was associated with lower likelihood of virological failure. The data revealed that CRF07_BC (1508, 95.62%) were the most common strains, and the drug-resistant rate was 32.10% among PLWH with virological failure in this area. The high frequencies of drug resistance were found in EFV and NVP of NNRTIs, ABC, FTC and 3TC of NRTIs, and TPV/r in PIs. The most common mutations in NNRTIs, NRTIs and PIs were K103N/KN (64.69%), M184V/MV/I (36.29%) and Q58E/QE (4.93%), respectively. We concluded that surveillance of virological failure, HIV-1 subtypes, and drug resistance to understand HIV-1 epidemiology and guide modification of ART guidelines, and target prevention and control strategies should be formatted to reduce the virological failure and drug resistance to promote viral suppression and prevent HIV-1 transmission.
Sections du résumé
BACKGROUND
BACKGROUND
Liangshan Yi Autonomous Prefecture is one of the areas that most severely affected by human immunodeficiency virus (HIV) in China, and virological failure on antiretroviral therapy (ART) is serious in this area. Analyses of prevalence and determinants of ART failure, the genetic diversity and drug resistance among people living with HIV (PLWH) helps improve HIV treatment efficiency and prevent HIV transmission.
METHODS
METHODS
A total of 5157 PLWH were recruited from 2016 to 2017. The venous blood samples were subjected to RT-PCR, followed by sequencing of the HIV-1 pol gene, targeting the protease and reverse transcriptase fragments. HIV-1 diversity was analyzed using the DNAStar software and drug resistance mutations were analyzed using the Stanford University HIV Drug Resistance Database.
RESULTS
RESULTS
A total of 2156 (41.81%) PLWH showed virological failure on ART. Males (ORm = 1.25), heterosexual behaviors and drug injection (ORm = 1.44) and mother to child transmission routes (ORm = 1.58), the clinical stage of AIDS (ORm = 1.35), having used illicit drugs and shared the needles (1-4 times: ORm = 1.34; more than 5 times: ORm = 1.52), having ever replaced ART regimen (ORm = 1.48) increased the risk of virological failure among PLWH, while higher education lever (ORm = 0.77) and ≥ 12 months on ART (12 ~ 36 months: ORm = 0.72; ≥36 months: ORm = 0.66) was associated with lower likelihood of virological failure. The data revealed that CRF07_BC (1508, 95.62%) were the most common strains, and the drug-resistant rate was 32.10% among PLWH with virological failure in this area. The high frequencies of drug resistance were found in EFV and NVP of NNRTIs, ABC, FTC and 3TC of NRTIs, and TPV/r in PIs. The most common mutations in NNRTIs, NRTIs and PIs were K103N/KN (64.69%), M184V/MV/I (36.29%) and Q58E/QE (4.93%), respectively.
CONCLUSION
CONCLUSIONS
We concluded that surveillance of virological failure, HIV-1 subtypes, and drug resistance to understand HIV-1 epidemiology and guide modification of ART guidelines, and target prevention and control strategies should be formatted to reduce the virological failure and drug resistance to promote viral suppression and prevent HIV-1 transmission.
Identifiants
pubmed: 32576136
doi: 10.1186/s12879-020-05124-1
pii: 10.1186/s12879-020-05124-1
pmc: PMC7310496
doi:
Substances chimiques
Anti-HIV Agents
0
Reverse Transcriptase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
443Subventions
Organisme : National Natural Science Foundation of China
ID : 81703279
Organisme : Sichuan Science and Technology Program
ID : 2019YJ0148
Organisme : National Major Science and Technology Projects of China (CN)
ID : 2017ZX10201101
Références
Arch Virol. 2015 Aug;160(8):2051-61
pubmed: 26077516
PLoS One. 2012;7(12):e52373
pubmed: 23300654
Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Jun 6;52(6):668-672
pubmed: 29886691
J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e150-7
pubmed: 23572014
J Infect Dis. 2007 May 1;195(9):1283-93
pubmed: 17396997
Epidemiol Infect. 2018 Feb;146(3):339-344
pubmed: 29345606
Infect Genet Evol. 2016 Dec;46:292-307
pubmed: 27587334
PLoS One. 2018 Jan 30;13(1):e0192077
pubmed: 29381736
BMC Infect Dis. 2019 Apr 5;19(1):312
pubmed: 30953449
Trends Pharmacol Sci. 2002 Aug;23(8):381-8
pubmed: 12377580
Int J STD AIDS. 2014 Aug;25(9):662-668
pubmed: 24352130
Int J Epidemiol. 2010 Dec;39 Suppl 2:ii4-13
pubmed: 21113036
Am J Public Health. 1996 Aug;86(8):1116-22
pubmed: 8712271
J Infect. 2013 May;66(5):391-400
pubmed: 23103289
BMC Infect Dis. 2017 May 3;17(1):326
pubmed: 28468608
PLoS One. 2012;7(10):e47289
pubmed: 23056619
Virol J. 2019 Apr 25;16(1):51
pubmed: 31023323
J Infect Dis. 2013 Nov 1;208(9):1459-63
pubmed: 23904291
J Virol. 2000 Dec;74(23):11286-95
pubmed: 11070028
J Antimicrob Chemother. 2017 Jan;72(1):227-234
pubmed: 27742812
Zhonghua Liu Xing Bing Xue Za Zhi. 2016 Aug 10;37(8):1105-7
pubmed: 27539341
N Engl J Med. 2017 Oct 26;377(17):1605-1607
pubmed: 29069566
Zhonghua Yu Fang Yi Xue Za Zhi. 2015 Oct;49(10):901-6
pubmed: 26813724
J Clin Lab Anal. 2013 Sep;27(5):346-53
pubmed: 24038219
AIDS Res Hum Retroviruses. 2016 Sep;32(9):851-9
pubmed: 27080587
J Virol. 2008 Sep;82(18):9206-15
pubmed: 18596096
Viruses. 2014 Oct 24;6(10):4095-139
pubmed: 25341668
AIDS Res Ther. 2009 Apr 28;6:7
pubmed: 19400929
Sex Transm Infect. 2014 Nov;90(7):538-44
pubmed: 24619575
Medicine (Baltimore). 2019 Oct;98(43):e17585
pubmed: 31651864
PLoS One. 2017 Feb 9;12(2):e0171780
pubmed: 28182786
PLoS One. 2013;8(2):e55824
pubmed: 23418463
J Virol. 2000 Dec;74(23):11367-76
pubmed: 11070037
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Lancet. 1998 Apr 25;351(9111):1250
pubmed: 9643749
BMC Infect Dis. 2018 Feb 12;18(1):76
pubmed: 29433430
HIV Med. 2019 Oct;20(9):624-627
pubmed: 31240860
Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Dec;36(12):1345-50
pubmed: 26850386
Cent Afr J Med. 2014 May-Aug;60(5-8):29-36
pubmed: 26867253
J Infect Dis. 2011 Nov;204(9):1463-9
pubmed: 21921202
JAMA. 2014 Jul 23-30;312(4):410-25
pubmed: 25038359